Insider Selling: BioLife Solutions (NASDAQ:BLFS) Insider Sells $13,042.47 in Stock

BioLife Solutions, Inc. (NASDAQ:BLFS) insider Karen Foster sold 519 shares of the stock in a transaction on Tuesday, December 9th. The stock was sold at an average price of $25.13, for a total transaction of $13,042.47. Following the sale, the insider owned 192,319 shares of the company’s stock, valued at approximately $4,832,976.47. This trade represents a 0.27% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website.

BioLife Solutions Trading Up 1.6%

BLFS stock traded up $0.40 during midday trading on Wednesday, hitting $25.01. The stock had a trading volume of 296,709 shares, compared to its average volume of 445,500. The firm has a market cap of $1.20 billion, a P/E ratio of -357.23 and a beta of 1.93. The business has a fifty day moving average price of $26.39 and a two-hundred day moving average price of $24.51. BioLife Solutions, Inc. has a 1-year low of $19.10 and a 1-year high of $29.62.

Analyst Ratings Changes

Several equities research analysts recently commented on the company. Zacks Research lowered BioLife Solutions from a “strong-buy” rating to a “hold” rating in a research report on Monday, December 8th. HC Wainwright restated a “buy” rating and set a $32.00 price target on shares of BioLife Solutions in a report on Monday, November 24th. Wall Street Zen downgraded shares of BioLife Solutions from a “buy” rating to a “hold” rating in a research report on Sunday, November 30th. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of BioLife Solutions in a research report on Wednesday, October 8th. Four equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, BioLife Solutions presently has an average rating of “Moderate Buy” and an average price target of $30.75.

Hedge Funds Weigh In On BioLife Solutions

A number of institutional investors have recently modified their holdings of the company. Hantz Financial Services Inc. lifted its holdings in shares of BioLife Solutions by 54.1% in the 3rd quarter. Hantz Financial Services Inc. now owns 1,877 shares of the medical equipment provider’s stock worth $48,000 after purchasing an additional 659 shares in the last quarter. State of Wyoming raised its holdings in BioLife Solutions by 353.1% during the first quarter. State of Wyoming now owns 1,912 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 1,490 shares during the last quarter. Quarry LP raised its holdings in BioLife Solutions by 50.9% during the third quarter. Quarry LP now owns 2,113 shares of the medical equipment provider’s stock worth $54,000 after buying an additional 713 shares during the last quarter. US Bancorp DE lifted its stake in shares of BioLife Solutions by 243.7% in the first quarter. US Bancorp DE now owns 2,155 shares of the medical equipment provider’s stock valued at $49,000 after buying an additional 1,528 shares in the last quarter. Finally, Ameritas Investment Partners Inc. grew its holdings in shares of BioLife Solutions by 12.8% during the second quarter. Ameritas Investment Partners Inc. now owns 3,873 shares of the medical equipment provider’s stock valued at $83,000 after buying an additional 441 shares during the last quarter. 93.24% of the stock is owned by institutional investors and hedge funds.

About BioLife Solutions

BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company’s products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.